Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARTL NASDAQ:CDIO NASDAQ:GRTX NASDAQ:PLRZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTLArtelo Biosciences$9.25+2.3%$11.92$4.92▼$28.60$6.52M1.4678,833 shs13,417 shsCDIOCardio Diagnostics$3.87+2.2%$3.92$3.22▼$53.10$6.72M2.9434,034 shs6,837 shsGRTXGalera Therapeutics$0.02-7.4%$0.02$0.02▼$0.08$1.51M1.9190,052 shs364,798 shsPLRZPolyrizon$1.09+4.8%$1.02$0.55▼$1,200.00$6.53MN/A599,617 shs372,206 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTLArtelo Biosciences0.00%-2.22%-9.31%+45.58%+18.59%CDIOCardio Diagnostics0.00%+10.37%-0.15%-11.95%-65.56%GRTXGalera Therapeutics0.00%-9.09%-13.04%-22.78%-69.65%PLRZPolyrizon0.00%+6.86%0.00%+34.57%+108,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTLArtelo Biosciences3.1468 of 5 stars3.85.00.00.03.20.00.6CDIOCardio Diagnostics1.0602 of 5 stars0.03.00.00.03.31.70.6GRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTLArtelo Biosciences 3.60Strong Buy$24.00159.46% UpsideCDIOCardio Diagnostics 0.00N/AN/AN/AGRTXGalera Therapeutics 0.00N/AN/AN/APLRZPolyrizon 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest GRTX, CDIO, ARTL, and PLRZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/26/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/18/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.008/4/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $18.007/8/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/8/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$20.006/11/2025ARTLArtelo BiosciencesD Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold6/6/2025ARTLArtelo BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTLArtelo BiosciencesN/AN/AN/AN/A$5.31 per shareN/ACDIOCardio Diagnostics$40K170.46N/AN/A$7.10 per share0.55GRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/APLRZPolyrizonN/AN/AN/AN/A$315.05 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTLArtelo Biosciences-$9.83M-$19.05N/AN/AN/AN/A-497.68%-213.76%11/10/2025 (Estimated)CDIOCardio Diagnostics-$8.38MN/A0.00∞N/A-30,465.10%-72.78%-66.17%11/12/2025 (Estimated)GRTXGalera Therapeutics-$59.08M-$0.19N/A∞N/AN/AN/A-99.34%N/APLRZPolyrizon-$1.54MN/A0.00∞N/AN/AN/AN/AN/ALatest GRTX, CDIO, ARTL, and PLRZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025CDIOCardio Diagnostics-$1.80-$0.97+$0.83-$0.97$0.08 million$0.01 million8/13/2025Q2 2025ARTLArtelo Biosciences-$0.13-$5.61-$5.48-$5.61N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTLArtelo BiosciencesN/AN/AN/AN/AN/ACDIOCardio DiagnosticsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/APLRZPolyrizonN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTLArtelo BiosciencesN/A0.390.39CDIOCardio DiagnosticsN/A23.5223.52GRTXGalera TherapeuticsN/A9.749.74PLRZPolyrizonN/A10.1610.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTLArtelo Biosciences0.87%CDIOCardio Diagnostics8.06%GRTXGalera Therapeutics50.77%PLRZPolyrizonN/AInsider OwnershipCompanyInsider OwnershipARTLArtelo Biosciences5.80%CDIOCardio Diagnostics22.30%GRTXGalera Therapeutics12.90%PLRZPolyrizonN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTLArtelo Biosciences5700,000663,000Not OptionableCDIOCardio Diagnostics11.76 million1.37 millionNot OptionableGRTXGalera Therapeutics3075.46 million47.38 millionOptionablePLRZPolyrizonN/A5.99 millionN/AN/AGRTX, CDIO, ARTL, and PLRZ HeadlinesRecent News About These CompaniesPolyrizon Regains Nasdaq ComplianceAugust 14, 2025 | msn.comPolyrizon Ltd. Regains Compliance with Nasdaq Listing RequirementsAugust 14, 2025 | quiverquant.comQPolyrizon Regains Compliance with Nasdaq Listing RequirementsAugust 14, 2025 | globenewswire.comPolyrizon Ltd. Announces Special General Meeting for September 2025July 31, 2025 | tipranks.comPolyrizon stock soars after promising nasal allergy blocker test resultsJuly 23, 2025 | in.investing.comPolyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest StudyJuly 22, 2025 | globenewswire.comPolyrizon Ltd.: Polyrizon Retains Nasdaq Listing Following Hearings PanelJuly 15, 2025 | finanznachrichten.dePolyrizon retains Nasdaq listing following hearings panelJuly 15, 2025 | msn.comPolyrizon Retains Nasdaq Listing Following Hearings PanelJuly 15, 2025 | globenewswire.comPolyrizon’s nasal drug delivery system shows promising resultsJune 14, 2025 | uk.investing.comPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its ...June 12, 2025 | bakersfield.comBPolyrizon Reports Promising Results Demonstrating Successful Internasal Delivery of its Innovative Hydrogel Formulation for CNS TherapeuticsJune 12, 2025 | globenewswire.comPolyrizon Ltd. Receives Nasdaq Notification of Potential Delisting Due to Shareholder Dilution ConcernsMay 23, 2025 | quiverquant.comQPolyrizon Announces Receipt of Nasdaq Delisting NoticeMay 23, 2025 | globenewswire.comPolyrizon Ltd. Announces Reverse Share Split Effective May 27, 2025May 22, 2025 | tipranks.comPolyrizon Emerges with Positive Preclinical Data on Nasal Protection PlatformMay 21, 2025 | globenewswire.comPolyrizon Ltd. Announces Increase in Outstanding Shares Following Warrant ExercisesMay 14, 2025 | tipranks.comPolyrizon Ltd.: Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue TreatmentMay 13, 2025 | finanznachrichten.dePolyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue TreatmentMay 13, 2025 | globenewswire.comPolyrizon, Pheton, AirSculpt: Top 3 Healthcare Stocks With Soaring Weekly Retail InterestMay 5, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGRTX, CDIO, ARTL, and PLRZ Company DescriptionsArtelo Biosciences NASDAQ:ARTL$9.25 +0.21 (+2.32%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$15.30 +6.05 (+65.41%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.Cardio Diagnostics NASDAQ:CDIO$3.87 +0.08 (+2.22%) Closing price 08/29/2025 03:50 PM EasternExtended Trading$3.25 -0.62 (-16.11%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.Galera Therapeutics NASDAQ:GRTX$0.02 0.00 (-7.41%) As of 08/29/2025 03:26 PM EasternGalera Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and for patients with HNC undergoing standard-of-care radiotherapy. It also develops rucosopasem manganese (rucosopasem) to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania.Polyrizon NASDAQ:PLRZ$1.09 +0.05 (+4.81%) As of 08/29/2025 04:00 PM EasternPolyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
